Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 14441
Country/Region: Malawi
Year: 2015
Main Partner: Lighthouse Trust
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $2,917,316 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $510,409
Care: TB/HIV (HVTB) $55,132
Care: Pediatric Care and Support (PDCS) $7,150
Strategic Information (HVSI) $23,150
Health Systems Strengthening (OHSS) $65,190
Testing: HIV Testing and Counseling (HVCT) $283,692
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $65,144
Treatment: Adult Treatment (HTXS) $1,793,921
Treatment: Pediatric Treatment (PDTX) $113,528
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 58,279
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 17,522
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 15,589
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 15,579
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 113,622
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 105,790
HTS_TST By Test Result: Negative 2016 232,448
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 250,580
HTS_TST Sum of Aggregated Age/Sex <15 2016 31,168
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 219,412
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 250,580
HTS_TST Sum of Test Result disaggregates 2016 250,580
HTS_TST_POS By Test Result: Positive 2016 18,132
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 3,132
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 2,975
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 1,521
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 1,403
PMTCT_ARV Sum of New and Current disaggregates 2016 2,924
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 2,505
PMTCT_STAT By: Known positives at entry 2016 1,408
PMTCT_STAT By: Number of new positives identified 2016 1,722
PMTCT_STAT Number of new ANC and L&D clients 2016 40,834
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 38,792
PMTCT_STAT Sum of Positives Status disaggregates 2016 3,130
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 2,031
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 1,889
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 58,279
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 57,124
TX_CURR Age/Sex: <1 Female 2016 20
TX_CURR Age/Sex: <1 Male 2016 16
TX_CURR Age/Sex: 1-4 Female 2016 148
TX_CURR Age/Sex: 1-4 Male 2016 137
TX_CURR Age/Sex: 5-14 Female 2016 694
TX_CURR Age/Sex: 5-14 Male 2016 701
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 54,639
TX_CURR Sum of age/sex disaggregates 2016 54,639
TX_NEW Breastfeeding status 2016 972
TX_NEW By Age/Sex: <1 Female 2016 57
TX_NEW By Age/Sex: <1 Male 2016 53
TX_NEW By Age/Sex: 1-4 Female 2016 111
TX_NEW By Age/Sex: 1-4 Male 2016 127
TX_NEW By Age/Sex: 10-14 Female 2016 89
TX_NEW By Age/Sex: 10-14 Male 2016 78
TX_NEW By Age/Sex: 15-19 Female 2016 428
TX_NEW By Age/Sex: 15-19 Male 2016 117
TX_NEW By Age/Sex: 20-24 Female 2016 1,613
TX_NEW By Age/Sex: 20-24 Male 2016 199
TX_NEW By Age/Sex: 25-49 Female 2016 7,528
TX_NEW By Age/Sex: 25-49 Male 2016 4,400
TX_NEW By Age/Sex: 5-9 Female 2016 88
TX_NEW By Age/Sex: 5-9 Male 2016 101
TX_NEW By Age/Sex: 50+ Female 2016 598
TX_NEW By Age/Sex: 50+ Male 2016 733
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 16,320
TX_NEW Pregnancy status 2016 3,555
TX_NEW Sum of Age/Sex disaggregates 2016 16,320
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 13,123
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 16,320
Cross Cutting Budget Categories and Known Amounts Total: $170,000
Motor Vehicles: Purchased $120,000
Key Populations: MSM and TG $50,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs